 SAN CARLOS, Calif., June 08, 2022 GLOBE NEWSWIRE -- Iovance Biotherapeutics, Inc. NASDAQ: IOVA, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in June: 